Could NANOLOGIX INCORPORATED (OTCMKTS:NNLX) Change Direction After Less Shorts?

January 2, 2018 - By Hazel Jackson

The stock of NANOLOGIX INCORPORATED (OTCMKTS:NNLX) registered a decrease of 45.52% in short interest. NNLX’s total short interest was 7,900 shares in January as published by FINRA. Its down 45.52% from 14,500 shares, reported previously. With 35,600 shares average volume, it will take short sellers 0 days to cover their NNLX’s short positions.

It closed at $0.03 lastly. It is down 0.00% since January 2, 2017 and is . It has underperformed by 16.70% the S&P500.

NanoLogix, Inc., a biotechnology company, provides live cell and rapid diagnostics test kits that detects viable bacteria and other microorganisms. The company has market cap of $3.59 million. The companyÂ’s products include BioNanoPore kit, which employs a water permeable membrane that works with organic and inorganic molecules, as well as proteins; and FlatPack Petri Plates that are used for the isolation and cultivation of various fastidious and non-fastidious microorganisms, as well as displays growth of aerobic and anaerobic microorganisms. It currently has negative earnings. The Company’s products are used in medical, national defense, homeland security, pharmaceutical, industrial, veterinary, and environmental testing applications.

More important recent NanoLogix, Inc. (OTCMKTS:NNLX) news were published by: which released: “NanoLogix Offers EU, Hong Kong & PRC Petri FlatPack Packaging Patents For $35 …” on July 12, 2017, also published article titled: “Global Nanotechnology in Medical Applications Market, 2017-2022”, published: “NanoLogix Rapid Bacteria Test Unveiled at CAOG, Wins Judges Choice Award …” on November 01, 2016. More interesting news about NanoLogix, Inc. (OTCMKTS:NNLX) was released by: and their article: “Nanologix Inc. Sets New Standard for Extended Shelf Life of Petri-Plates” with publication date: February 24, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.